ABP-745 Dose A
DrugABP-745 Dose A - tablets (PO), low dose , QD
NCT Number: NCT07303777
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Phase 2
NovaTrails, Newcastle, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Unless otherwise specified, subjects must meet all of the following criteria at screening:
Exclusion criteria
Unless otherwise specified, subjects are excluded from the study if any of the following criteria is met:
ABP-745 Dose A - tablets (PO), low dose , QD
ABP-745 placebo - tablets (PO), non-active,QD
ABP-745 Dose B - tablets (PO), Midum dose, QD
ABP-745 Dose C - tablets (PO), High dose, QD
Time frame: 52 weeks after treatment
Time frame: 24 weeks after treatment
Time frame: up to 14 days post the last dose of study drug
Contact information is provided by the study sponsor or research team.
Atom Therapeutics Co., Ltd
Industry
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics (PopPK) Profile of ABP-745 in Patients With Atherosclerosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07665034
Arterial Occlusive Diseases, Arteriosclerosis
Shatin, Hong Kong
View Trial DetailsNCT07263113
Arterial Occlusive Diseases, Arteriosclerosis
Nantes, France
View Trial DetailsNCT07296965
Arterial Occlusive Diseases, Arteriosclerosis
Budapest, Hungary
View Trial DetailsNCT07361887
Alzheimer s Disease, Atherosclerosis Cardiovascular Disease
Seville, Sevilla, Spain
View Trial Details